A hospital’s published negotiated rate for a hip replacement is not a price. It is a price-per-payer, averaged across the procedural and geographic variation that any given contract contains, disclosed without the volume context that determines whether it matters.
This is not a pedantic distinction. A community hospital that negotiates a $40,000 rate for total joint replacement from a regional Blue Cross plan sounds, in isolation, expensive relative to a larger competitor charging $32,000. If the community hospital does forty joints a year and the competitor does four hundred, the rate difference is functionally irrelevant to any analysis of system-wide healthcare spending. But if that community hospital is the dominant orthopedic provider in a rural county—if it does those forty joints because it is the only facility within ninety miles—then the $40,000 rate is what economists call a monopoly premium, and the comparison is quite important.
MedPricer.org’s rate data becomes analytically powerful when paired with payer mix information—the proportion of a hospital’s volume derived from Medicare, Medicaid, commercial insurance, self-pay, and Medicare Advantage. This information is available, imperfectly, through Medicare cost reports and hospital financial filings. The pairing requires work. But the questions it enables are the right ones.
Consider what payer mix reveals about negotiated rate strategy. Hospitals with high Medicare and Medicaid volume have less leverage with commercial payers—their revenue base is more constrained, their capital position weaker, and their ability to walk away from contract negotiations more limited. The commercial rates they negotiate often reflect this; they are frequently lower than those of their competitors with richer payer mixes, even controlling for case mix index and geography.
Private equity-backed hospital systems have, in documented cases, pursued a different strategy: selectively contracting with high-margin commercial payers while disproportionately shedding Medicaid volume. MedPricer’s rate data, cross-referenced with payer mix trends from cost reports, can reveal whether a system’s commercial rates are rising in concert with declining Medicaid share—a pattern that has significant policy implications and that conventional hospital financial reporting does not surface.
For journalists, this creates a specific investigative frame. Rather than asking whether Hospital A’s rates are high, the more useful question is whether the relationship between Hospital A’s payer mix and its commercial rates is consistent with a strategy of cost-shifting—pricing commercial payers higher to subsidize underpayment by government programs—or with a strategy of selective contracting. The data cannot definitively answer this; only interviews with hospital executives and payer contract teams can. But data-informed questioning produces different conversations than uninformed questioning.
The Medicare Advantage wrinkle adds another layer. MA plans, which now cover more than half of Medicare beneficiaries nationally, negotiate rates with hospitals independently—and those rates are typically lower than commercial rates but higher than traditional Medicare rates. How hospitals price for MA relative to commercial plans reveals something about their assessment of MA’s growth trajectory and their leverage within it.
The MedPAC analysis of Medicare Advantage payment accuracy has raised persistent questions about overpayment to MA plans relative to traditional Medicare—overpayments that flow, in part, from coding upcoding that inflates risk scores. Hospitals operating in high-MA markets have strong incentives to accommodate MA plans’ administrative requirements, which affects their negotiating posture. A rate analysis that doesn’t account for MA’s expanding share of hospital volume is likely to misinterpret what it sees.
None of this complexity argues against using price transparency data. It argues against using it naively. MedPricer’s value is not that it simplifies the analysis—it is that it makes the relevant complexity accessible to analysts who are prepared to engage with it.
The payer mix problem is ultimately a reminder that healthcare markets are deeply local, structurally heterogeneous, and poorly described by national averages. A tool that disaggregates to the procedure level, the payer level, and the geographic level—and that can be paired with external data sources—is not simplifying something complicated. It is providing the granularity that the complication requires.
